January 1, 2014Thrombosis and Haemostasis

Therapeutic dose bridging was associated with similar thromboembolic risk (OR 0.90; 95% CI, 0.37 to 2.18, p=0.81) but increased major bleeding (OR 3.23; 95% CI, 1.58 to 6.62; p=0.001) compared to prophylactic dose bridging.

View Full Paper

Ask AI

Bookmark

Why the study?

Does therapeutic dose bridging parenteral anticoagulation reduce thromboembolism compared to prophylactic dose bridging in patients after mechanical valve replacement?

Population

1777 patients undergoing mechanical heart valve replacement at five Canadian hospitals between 2003 and 2010.

Comparison

Therapeutic dose bridging parenteral… vs Prophylactic dose bridging parenteral…

Design

Cohort

Follow-up

30-days

Authors

JMJoseph P. Mathew ASAlex C. Spyropoulos AYArif M. Yusuf

Discussion

Member takes

Overview

May increase bleeding without thromboembolic benefit after mechanical valve replacement; leaves open optimal bridging strategy pending randomized trials.

Structured PICO

Does therapeutic dose bridging parenteral anticoagulation reduce thromboembolism compared to prophylactic dose bridging in patients after mechanical valve replacement?

Population

1777 patients undergoing mechanical heart valve replacement (MVR) at five Canadian hospitals between 2003 and 2010.

Intervention

Therapeutic dose bridging parenteral anticoagulation early after mechanical valve replacement

Comparator

Prophylactic dose bridging parenteral anticoagulation

Outcome

Thromboembolism (composite of stroke, transient ischaemic attack, systemic embolism or valve thrombosis) at 30-dayscomposite

Therapeutic dose bridging after mechanical valve replacement increases major bleeding without reducing thromboembolic events compared to prophylactic dosing.

Cite This Study

Mathew et al. (2014) studied this question.

synapsesocial.com/papers/6a709f79ac440176ef2949ee https://doi.org/10.1160/th14-03-0284

View Full Paper

Ask AI

Bookmark

January 1, 2014Thrombosis and Haemostasis

Therapeutic dose bridging was associated with similar thromboembolic risk (OR 0.90; 95% CI, 0.37 to 2.18, p=0.81) but increased major bleeding (OR 3.23; 95% CI, 1.58 to 6.62; p=0.001) compared to prophylactic dose bridging.

View Full Paper

Ask AI

Bookmark

Why the study?

Does therapeutic dose bridging parenteral anticoagulation reduce thromboembolism compared to prophylactic dose bridging in patients after mechanical valve replacement?

Population

1777 patients undergoing mechanical heart valve replacement at five Canadian hospitals between 2003 and 2010.

Comparison

Therapeutic dose bridging parenteral… vs Prophylactic dose bridging parenteral…

Design

Cohort

Follow-up

30-days

Authors

JMJoseph P. Mathew ASAlex C. Spyropoulos AYArif M. Yusuf

Discussion

Member takes

Overview

May increase bleeding without thromboembolic benefit after mechanical valve replacement; leaves open optimal bridging strategy pending randomized trials.

Structured PICO

Does therapeutic dose bridging parenteral anticoagulation reduce thromboembolism compared to prophylactic dose bridging in patients after mechanical valve replacement?

Population

1777 patients undergoing mechanical heart valve replacement (MVR) at five Canadian hospitals between 2003 and 2010.

Intervention

Therapeutic dose bridging parenteral anticoagulation early after mechanical valve replacement

Comparator

Prophylactic dose bridging parenteral anticoagulation

Outcome

Thromboembolism (composite of stroke, transient ischaemic attack, systemic embolism or valve thrombosis) at 30-dayscomposite

Therapeutic dose bridging after mechanical valve replacement increases major bleeding without reducing thromboembolic events compared to prophylactic dosing.

Cite This Study

Mathew et al. (2014) studied this question.

synapsesocial.com/papers/6a709f79ac440176ef2949ee https://doi.org/10.1160/th14-03-0284

View Full Paper

Ask AI

Bookmark